Experimental achondroplasia drug trial halted early

NCT ID NCT06067425

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called SAR442501 in children with achondroplasia, a common form of dwarfism. The goal was to see if the drug was safe and could improve growth. However, the trial was stopped early after enrolling only 16 children, so we have very little information about how well it worked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR442501 (an experimental drug given as a shot under the skin)
What this could lead to: If successful, this drug could help children with achondroplasia grow more, potentially reducing some health complications.
What could go wrong: The trial was terminated early with only 16 participants, so results are very limited. It is unclear if the drug is safe or effective, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

achondroplasia osteochondrodysplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOCHONDRODYSPLASIA

Contacts and locations

Locations

Investigational Site Number : 0360001

Parkville, Victoria, 3052, Australia
Investigational Site Number : 1560001

Wuhan, 430030, China
Investigational Site Number : 1560002

Shanghai, 200120, China
Investigational Site Number : 3800001

Rome, Roma, 00168, Italy
Investigational Site Number : 3800002

Milan, Lombardy, 20122, Italy
Investigational Site Number : 4100001

Seoul, Seoul-teukbyeolsi, 03080, South Korea
Investigational Site Number : 4100002

Seoul, Seoul-teukbyeolsi, 06351, South Korea
Investigational Site Number : 7240001

Esplugues de Llobregat, Catalunya [Cataluña], 08950, Spain
Investigational Site Number : 7240002

Vitoria-Gasteiz, Basque Country, 01008, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.